Indeed, the treatment of drug-resistant ovarian cancer cells with diethylaminobenzaldehyde (DEAB), an inhibitor of ALDH1, downregulated BCRP and MDR1 levels with concomitant elevation in drug sensitivity21. Here, ALDH1A1 is linked to ovarian cancer.